Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Filed with HKEX · Stock code 1228 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorized share capital and provides details on issued shares and treasury shares. The report indicates that there were no changes in the number of issued or treasury shares during the month. Additionally, it confirms compliance with public float requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CANbridge Pharmaceuticals Inc. on 6ix
Earlier from CANbridge Pharmaceuticals
- Interim report 2026
- CANbridge Announces NHIA Reimbursement Approval of Livmarli for Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Taiwan
- CANbridge Announces Strategic Partnership and Investment from Baheal to Strengthen Commercialization of Rare Disease Products
- CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
- CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
Follow CANbridge Pharmaceuticals into a list and get an email when it puts out news.
Follow CANbridge Pharmaceuticals